Geneva, November 13, 2023 – In the week ahead, IGBA will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines which contribute to delivering better health outcomes and biologics access equity for more patients. The fourth Global Biosimilars Week (GBW) will run from 13th to 17th November, 2023 on social media, supported by a rich resource dedicated website globalbiosimilarsweek.org.
On October 27, 2023, the International Generics and Biosimilars Medicines Association (IGBA), including members of IGBA’s CEO Advisory Committee, met with World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus in Geneva. During the full-day meeting, IGBA company and member association representatives, together with WHO technical experts, discussed steps both organizations can take together to expand global access to generic and biosimilar medicines.
The International Generic and Biosimilar Medicines Association’s (IGBA) CEO Advisory Committee held an exchange with Mr. Daren Tang, Director General of the World Intellectual Property Organization (WIPO). This was the first opportunity for Mr. Tang to engage in a direct dialogue with IGBA CEO Advisory Committee Members.
- ANAFAM, the National Association of Medicines Manufacturers of Mexico, joins IGBA (September 2023)
- Global regulators and biopharmaceutical and vaccine industry to share experiences with managing pharmaceutical quality systems (July 2023)
- IGBA Welcomes ICH New Topic for Harmonisation: “Bioequivalence for Modified-Release Products” (June 2023)
- IGBA CEO Advisory Committee Vienna Statement - Four Keys to More Predictable Supply Chains (June 2023)